|
Yongshi: A Wild Boar Peptide with Anti-Viral Activity Targeting COVID-19
Application
An antiviral cathelicidin peptide from wild boar that exhibits antiviral properties against SARS-CoV-2.
Key Benefits
Pan-coronavirus inhibitor that may be effective for all future variants.
Functions as an inhibitor of ongoing infection.
Early data suggests it is safe to use in human tissue.
Market Summary
Coronavirus disease...
Published: 4/23/2024
Contributor(s): Joshy Jacob, Mehul Suthar, Troy Von Beck, Nikita Mullick, Abigail Vanderheiden, Jeffrey Skolnick
|
|
Frog Skin Peptides for Treatment of Human Influenza Viruses
Application
A therapeutic peptide that treats Influenza A virus
Key Benefits
New method of action compared to antiviral drugs currently in use.
Therapeutic peptide is virucidal against drug resistant strains.
Market Summary
Worldwide seasonal influenza epidemics can impact 5 – 15% of the population. The occurrence of vaccine mismatch...
Published: 4/23/2024
Contributor(s): Joshy Jacob, David Holthausen, Song Lee, Sanil George
|
|
Frog Skin Peptides for Treatment of Zika Viruses
Application
A therapeutic peptide that treats Zika Virus.
Key Benefits
Potential therapeutic to fight against the growing threat of the Zika virus.
Peptide is fast acting and destroys Zika virions within 5 minutes of exposure.
Market Summary
Zika is an infectious disease spread primarily by Aedes mosquitoes and results in symptoms similar to...
Published: 4/23/2024
Contributor(s): Joshy Jacob, Song Lee, David Holthausen, Sanil George
|